Can BDA’s medical cannabis product treat long-COVID symptoms?
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Bod Australia Limited (ASX: BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of long-term symptoms of COVID-19.
BDA is a medicinal cannabis, CBD and hemp healthcare products company operating within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.
As we reported yesterday, BDA has an exclusive global partnership with Health & Happiness (H&H) Group, which owns a number of powerful consumer brands in the health and wellness space including iconic Australian brand Swisse through which it sells a range of consumer products.
Today’s announcement focuses on its medical cannabis division.
BDA’s pharmaceutical-grade, medicinal cannabis is currently available in Australia and the UK and during H1 FY2021, BDA filled a total of 3,941 MediCabilisTM prescriptions, highlighting a 114% increase on the previous corresponding year.
Treating long-COVID
Today’s announcement states that Drug Science UK will assess the efficacy of BDA’s medicinal cannabis, MediCabilis®, in managing symptoms associated with the long term impact of COVID-19 – known as long-COVID.
Founded in 2010 by Professor David Nutt, Drug Science is the only completely independent, science-led drugs charity in the UK.
Drug Science brings together leading experts to help create the foundation for sensible and effective evidence based drug laws free from political and commercial influence.
BDA already has a longstanding relationship with Drug Science and was a founding launch partner of Project Twenty21, a medicinal cannabis registry that aims to create the UK’s largest body of evidence for the effectiveness and tolerability of medicinal cannabis.
Long-COVID refers to the lengthy time it takes for people who experience symptoms of COVID-19 to recover. This can be weeks or even months.
Common symptoms include sleep disturbances, chronic pain, anxiety and fatigue – all symptoms that may be treatable with cannabis based medicinal products.
Currently, there is no treatment for symptoms associated with long-COVID.
However, there is an urgent need to identify and study potential ways to manage this emerging clinical condition.
MediCabilis® is currently used to treat a range of conditions including pain and anxiety and the Company is confident that the product may assist with people suffering from long-COVID.
As stated above, this collaboration could unlock a new market for BDA in the treatment of long-COVID. It is estimated that one in 10 people that test positive for COVID-19 will have symptoms for 12 weeks after diagnosis and that one in five have long-COVID symptoms for five weeks or more.
“While much progress has been made in the treatment of COVID-19, the effects of the disease are expected to continue into the foreseeable future and symptoms are likely to linger for many patients,” BDA CEO Jo Patterson said.
“This collaboration with Drug Science will not only strengthen the body of evidence for the use of MediCabilis®, but also potentially address the growing unmet health concerns around long-COVID.
“MediCabilis® is currently being prescribed for a number of chronic conditions and we are confident that this initiative will provide patients with a pathway to manage the effects of long-COVID and improve their quality of life.”
Commencement of the trial and first patient recruitments will begin in the coming months.
This type of study certainly has the backing of the UK government, with NHS England recently investing £10M ($17.8M) in specialist long-COVID clinics.
“We are excited to have entered into this collaboration agreement with Bod Australia to explore the efficacy of medicinal cannabis on long-COVID symptoms,” Drug Science Founder, Professor David Nutt said.
“Bod has a scientific approach, that aligns well with Drug Science. We look forward to working with the Company to further explore the benefits of cannabinoid based products on chronic conditions including pain, anxiety and fatigue.”
As part of the collaboration agreement, BDA will sponsor the proposed clinical study and provide its MediCabilis® product to participants at a cost that it does not expect to be material.
BDA and Drug Science UK will collaborate on trial design, and Drug Science will provide its extensive scientific expertise, independent doctors and scientists and conduct the study according to Good Clinical Practice standards through an approved cannabis prescriber in the UK.
Drug Science will also be responsible for the collection and analysis of all data.
For a complete analysis of BDA overall business click through to the Wise Owl report below:
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
